Evidence map›Paper›PMID 26491157›Full record

ArticleJournal of virology2016

Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity.

Susan Zolla-Pazner, Sandra Sharpe Cohen, David Boyd, Xiang-Peng Kong, Michael Seaman, Michel Nussenzweig, Florian Klein, Julie Overbaugh, Max Totrov

Open access · hybridAbstract read
In one paragraph

Article in Journal of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 77 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Susan Zolla-PaznerVeterans Affairs New York Harbor Healthcare System, New York, New York, USA Departments of Pathology and Biochemistry, New York University School of Medicine, New York, New York, USA Susan.Zolla-Pazner@mssm.edu.ORCID http://orcid.org/0000-0002-0750-2666
Sandra Sharpe CohenDepartments of Pathology and Biochemistry, New York University School of Medicine, New York, New York, USA.
David BoydFred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Xiang-Peng KongDepartments of Pathology and Biochemistry, New York University School of Medicine, New York, New York, USA.
Michael SeamanBeth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Michel NussenzweigThe Rockefeller University, New York, New York, USA.
Florian KleinThe Rockefeller University, New York, New York, USA.
Julie OverbaughFred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Max TotrovMolsoft, L.L.C., San Diego, California, USA.
Fred Hutch Cancer Center · USNew York University · USRockefeller University · USBeth Israel Deaconess Medical Center · USMolsoft (United States) · USVA NY Harbor Healthcare System · US

Funding

Stuctural basis of bNab activityP01AI100148 · NIAID · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI Pamela J Bjorkman · 2013 to 2026
$43.3M
Vaccines to Induce Functional Antibodies Targeting the V2 Loop P01AI100151 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WANG, SHIXIA · 2012 to 2017
$15.4M
PROTECTIVE HUMAN MONOCLONAL ANTIBODIES TO HIV1R01HL059725 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ZOLLA-PAZNER, SUSAN B · 1997 to 2014
$8.8M
CHARACTERIZATION OF HIV-1 ANTIBODY RESPONSES IN CHRONICALLY INFECTED WOMENR01AI103981 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI OVERBAUGH, JULIE M. · 2012 to 2015
$2.8M
Viral Pathogenesis Training ProgramT32AI083203 · NIAID · UNIVERSITY OF WASHINGTON · PI BLOOM, JESSE D, LAGUNOFF, MICHAEL · 2009 to 2023
$2.7M
Howard Hughes Medical InstituteNHLBI NIH HHS R01 HL059725NHLBI NIH HHS R01 HL59725NIAID NIH HHS AI103981NIAID NIH HHS P01 AI100148NIAID NIH HHS P01 AI100151NIAID NIH HHS R01 AI103981NIAID NIH HHS T32 AI083203
6 · The paper itself

Abstract

unlabelledAntibodies (Abs) specific for the V3 loop of the HIV-1 gp120 envelope neutralize most tier 1 and many tier 2 viruses and are present in essentially all HIV-infected individuals as well as immunized humans and animals. Vaccine-induced V3 Abs are associated with reduced HIV infection rates in humans and affect the nature of transmitted viruses in infected vaccinees, despite the fact that V3 is often occluded in the envelope trimer. Here, we link structural and experimental data showing how conformational alterations of the envelope trimer render viruses exceptionally sensitive to V3 Abs. The experiments interrogated the neutralization sensitivity of pseudoviruses with single amino acid mutations in various regions of gp120 that were predicted to alter packing of the V3 loop in the Env trimer. The results indicate that the V3 loop is metastable in the envelope trimer on the virion surface, flickering between states in which V3 is either occluded or available for binding to chemokine receptors (leading to infection) and to V3 Abs (leading to virus neutralization). The spring-loaded V3 in the envelope trimer is easily released by disruption of the stability of the V3 pocket in the unliganded trimer or disruption of favorable V3/pocket interactions. Formation of the V3 pocket requires appropriate positioning of the V1V2 domain, which is, in turn, dependent on the conformation of the bridging sheet and on the stability of the V1V2 B-C strand-connecting loop. IMPORTANCE: The levels of antibodies to the third variable region (V3) of the HIV envelope protein correlate with reduced HIV infection rates. Previous studies showed that V3 is often occluded, as it sits in a pocket of the envelope trimer on the surface of virions; however, the trimer is flexible, allowing occluded portions of the envelope (like V3) to flicker into an exposed position that binds antibodies. Here we provide a systematic interrogation of mechanisms by which single amino acid changes in various regions of gp120 (i) render viruses sensitive to neutralization by V3 antibodies, (ii) result in altered packing of the V3 loop, and (iii) activate an open conformation that exposes V3 to the effects of V3 Abs. Taken together, these and previous studies explain how V3 antibodies can protect against HIV-1 infection and why they should be one of the targets of vaccine-induced antibodies.

Indexed as

Amino Acid SubstitutionAntibodies, NeutralizingHIV-1HIV AntibodiesHIV Envelope Protein gp120Models, MolecularMutant ProteinsProtein ConformationAntibodies, Neutralizinggp120 protein, Human immunodeficiency virus 1HIV AntibodiesHIV Envelope Protein gp120Mutant Proteins

Identifiers

PMID26491157
PMCPMC4702699
OpenAlexW2277500758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.